Posts

Metsera’s New Obesity Data Raises Efficacy Profile, Key Side Effect Questions for Pfizer After Acquisition

on

Barinthus Biotherapeutics Announces Reverse Merger with Clywedog Therapeutics to Form New Metabolic Disease-Focused Company

on

Merck Makes Strong Case for Winrevair in Earlier-Stage Pulmonary Arterial Hypertension (PAH) Patients After Positive Phase 3 HYPERION Results

on

Crystalys Lands $205M to Advance Gout Drug Dotinurad

on

AstraZeneca Plans Direct US Stock Listing While Maintaining UK Headquarters

on

Enanta Presses Ahead with RSV Drug Zelicapavir Despite Missing Primary Endpoint in Phase IIb Trial

on

IO Biotech Sheds 50% of Staff After FDA Blocks Cancer Vaccine Approval Path

on

Novartis and Boehringer Ingelheim Launch Direct-to-Consumer Drug Sales, Bypassing Middlemen

on

Tourmaline Attracted Bidding War Before $1.4B Acquisition by Novartis

on

MoonLake shares crash after mixed results in pivotal hidradenitis suppurativa studies

on

GSK Appoints Luke Miels as New CEO, Succeeding Emma Walmsley on Jan. 1, 2026

on

Genmab CEO on the $8B Acquisition of Merus: Strategy Behind the 'Very Fair' Deal and Plans to Polish a Rough Diamond

on

White House ‘Most Favored Nation’ Deadline Drives Pharma Concessions Amid Threats of Enforcement

on

Rezon Bio Launches Two State-of-the-Art CDMO Facilities for Biologics in Europe

on

Continuous Bioprocessing for Bispecific Antibodies: Innovations Accelerating Therapeutic Antibody Production (2024–2025)

on

Biogen Shuffles Staff and Exits AAV Gene Therapy Programs After Strategic Shift

on

GSK CEO Emma Walmsley Steps Down After 9 Years; Luke Miels to Succeed

on

New Confirmatory Study Suggests Progress in Applied Therapeutics–FDA Alignment for Rare Disease Drug

on

Sanofi Expands $35 Insulin Program to All U.S. Patients Nationwide

on

Eli Lilly's Oral SERD Inluriyo Approved by FDA for ESR1-Mutated Breast Cancer

on

Trump Administration Teases MFN Drug Pricing Rule as Commitment Deadline Looms for Companies

on

Kai Beckmann Appointed as Successor to Merck KGaA CEO Belén Garijo, Effective May 2026

on

Thyme Care Raises $97 Million Series D to Drive AI-Powered Oncology Care at $1B Valuation

on

AstraZeneca Appeals to Supreme Court in Final Attempt to Challenge Medicare Drug Price Negotiation Program

on

Eli Lilly Withdraws $1.9B Phase 2b Obesity Trial Before Launching Enrollment

on

Trump Administration Launches Tariff Probe into Medtech and Pharmaceutical Industries

on

Pfizer's $4.9B Metsera Deal Signals More Pharma M&A in Booming Obesity Drug Market

on

Catalent Opens New Global HQ; Fujifilm Launches North Carolina Factory

on

Eli Lilly Invests $6.5 Billion in Texas Facility to Manufacture Obesity Pill

on

Getting to Yes: How Deal-Making Fuels Biotech Growth – 2025 Updates

on

Rising Pharmaceuticals Lowers Headcount After Closing Decatur Factories

on

Glenmark Pharma Signs $1.1 Billion Deal with Hengrui for HER2-Targeted Antibody-Drug Conjugate

on

Acadia Pulls Plug on Prader-Willi Drug After Phase 3 Trial Failure

on

Placebo Response Trips Up Harmony Biosciences’ Fragile X Drug in Late-Stage Phase 3 Trial

on

Sparrow Pharmaceuticals Raises $95M Series B for Midstage Diabetes Study

on

uniQure's Gene Therapy AMT-130 Significantly Slows Huntington's Progression in Pivotal Trial

on

Acadia Halts Development of Nasal Prader-Willi Drug After Phase 3 Failure

on

Biogen Plans Resubmission After FDA Declines High-Dose Spinraza for SMA, Requests More Production Information

on

Sanofi Injects $625M Into Biotech Investment Arm to Accelerate Innovation

on

FDA's Move to Update GSK's Leucovorin for Autism Raises Questions on Dose, Supply, and Data

on